drugset / Trial / NCT00996879

Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects

NCT00996879

Phase 1 Completed 48 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-label

Summary

The purpose of this study is to assess the effect of BMS-791325 on the pharmacokinetics of the CYP3A4 Probe Midazolam.

Timeline

Start
2013-05
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Beclabuvir Small molecule 300 mg Oral
Subject Midazolam Small molecule 5 mg Oral